Sanofi widens marketing team for slow starter Kynamro

Sales of Sanofi's ($SNY) rare-disease treatment Kynamro, approved last January, got off to a slow start. But that situation shouldn't persist now that the French drugmaker's Genzyme unit has beefed up its sales force, says Lynne Parshall, COO of development partner Isis Pharmaceuticals ($ISIS). "Sales showed significant quarter-over-quarter growth in 2013, and we believe the sales will continue to increase significantly this year," she said on last week's earnings call. More